ACA vs BMRN · P/E 57, rev $2.88B vs P/E 40, rev $2.85B
Arcosa Inc (ACA) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Arcosa Inc (ACA) is a engineering & construction company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported ACA revenue for 2025-12-31 was $2.88B. Net income was $208.4M. Revenue was up 12.2% from 2024-12-31 to 2025-12-31. ACA currently screens at market cap $4.39B and trailing P/E 56.6.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
ACA currently screens at market cap $4.39B and trailing P/E 56.6. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the ACA and BMRN stock pages for the full models.
Not investment advice.